Robert A. Levine, MD

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, share final thoughts and takeaways on the treatment of rheumatoid arthritis in the community setting.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, review the integration of precision medicine into the management of rheumatoid arthritis.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, discuss barriers to rheumatoid arthritis (RA) treatment selection such as insurance access.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine share their thoughts on how MSRC test results impact the treatment selection for patients with RA.

Experts in rheumatology review the molecular signature response classifier (MSRC) test for use in guiding RA treatment selection.

Nehad Soloman, MD, leads a discussion about precision medicine in the treatment arsenal for RA.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, discuss American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) recommendations regarding appropriate timing when changing therapies in managing RA.

Rheumatology specialists review factors in switching a patient with RA to a different treatment, including timing, efficacy assessment, and barriers.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, examine potential risks in continuing a patient on an ineffective treatment in RA.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine share insights on how to measure treatment efficacy in the management of RA.

Rheumatology experts discuss the potential roadblocks to treatment of RA, such as insurance access.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levine, MD, review how the increase in treatment options for RA has led to a trial-and-error approach to treatment.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine describe the treatment path from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to biologic or targeted disease-modifying antirheumatic drugs (b/tsDMARDs) for a typical rheumatoid arthritis (RA) patient.